Spark Therapeutics, Inc.

Clinical trials sponsored by Spark Therapeutics, Inc., explained in plain language.

Now part of Roche Holding AG RHHBY OTC

A gene therapy company (acquired by Roche) developing treatments for genetic diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

Gene therapy safety check: luxturna registry wraps up

Knowledge-focused Completed

This completed study tracked 87 patients who received Luxturna gene therapy for a rare inherited eye condition that causes blindness. Researchers monitored side effects and pregnancy outcomes for up to 5 years after treatment. The goal was to gather real-world safety data, not to…

Sponsor: Spark Therapeutics, Inc. • Aim: Knowledge-focused

Last updated Jun 27, 2026 07:51 UTC

Spark Therapeutics, Inc.

Gene therapy safety check: luxturna registry wraps up